All In Biotech

Drug Trial Radar · NCT06305780

RECOVER-AUTONOMIC Platform Protocol

RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 381 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

381

Actual

Start

Mar 11, 2024

Primary completion

Jul 9, 2025

Study completion Jul 9, 2025

Sponsor

Lead sponsor
Kanecia Obie ZimmermanAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

Conditions

  • Long COVID
  • Long Covid19
  • Long Covid-19

Interventions

  • IVIG + Coordinated CareDrug

    Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.

  • IVIG Placebo + Coordinated CareDrug

    Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration. Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.

  • Ivabradine + Coordinated CareDrug

    Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

  • Ivabradine Placebo + Coordinated CareDrug

    The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator.

  • IVIG + Usual CareDrug

    Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.

  • IVIG Placebo + Usual CareDrug

    Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG. Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.

  • Ivabradine + Usual CareDrug

    Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.

  • Ivabradine Placebo + Usual CareDrug

    The control (placebo) oral tablets will be similar to the study drug, ivabradine. The control packaging matches the packaging. Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Number of Participants Enrolled in Each AppendixTime frame: During the enrollment period, approximately 16 months

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • East Alabama Medical Center - Appendix B Only

    Opelika, Alabama

  • Center for Complex Neurology - Appendix A & B

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences - Appendix A & B

    Little Rock, Arkansas

  • University of California San Diego - Appendix B Only

    La Jolla, California

  • Cedars Sinai Medical Center - Appendix A & B

    Los Angeles, California

  • Stanford University - Appendix B Only

    Stanford, California

  • University of Colorado Anschutz Medical Campus Clinical and Translational Research Center (CTRC) - Appendix A & B

    Aurora, Colorado

  • MedStar National Rehabilitation Hospital - Appendix B only

    Washington D.C., District of Columbia

  • University of Florida Health - Appendix A & B

    Gainesville, Florida

  • Lakeland Regional Medical Center - Appendix A & B

    Lakeland, Florida

  • Innovation Clinical Trials Inc.- Appendix A & B

    Palmetto Bay, Florida

  • Grady Memorial Hospital - Woodruff Memorial Research - Appendix A & B

    Atlanta, Georgia

  • Morehouse School of Medicine - Appendix A & B

    Atlanta, Georgia

  • Queens Medical Center - Appendix B Only

    Honolulu, Hawaii

  • Rush University Medical Center - Appendix B Only

    Chicago, Illinois

  • University of Illinois at Chicago - Appendix A & B

    Chicago, Illinois

  • NorthShore University HealthSystem - Evanston Hospital - Appendix B Only

    Evanston, Illinois

  • University of Iowa - Appendix A & B

    Iowa City, Iowa

  • University of Kansas Medical Center CTSU Fairway - Appendix A & B

    Fairway, Kansas

  • University of Kentucky Medical Center - Appendix A & B

    Lexington, Kentucky

  • University Medical Center New Orleans - Appendix A & B

    New Orleans, Louisiana

  • Johns Hopkins Hospital - Appendix A Only

    Baltimore, Maryland

  • Brigham and Women's Hospital - Appendix A Only

    Boston, Massachusetts

  • Henry Ford Hospital - Appendix A & B

    Detroit, Michigan

  • Mayo Clinic - Appendix A & B

    Rochester, Minnesota

  • University of Mississippi Medical Center - Appendix A & B

    Jackson, Mississippi

  • Washington University School of Medicine - Appendix B Only

    St Louis, Missouri

  • University at Buffalo - Appendix A & B

    Buffalo, New York

  • St. Lawrence Health Medical Campus - Appendix A & B

    Canton, New York

  • Columbia University Irving Medical Center - Appendix A & B

    New York, New York

  • Stony Brook University Hospital - Appendix A & B

    Stony Brook, New York

  • Montefiore Medical Center - Moses Campus - Appendix B

    The Bronx, New York

  • Duke University Hospital - Appendix A & B

    Durham, North Carolina

  • East Carolina University - Appendix B Only

    Greenville, North Carolina

  • Cleveland Clinic - Appendix A & B

    Cleveland, Ohio

  • University of Oklahoma Health Science Center - Oklahoma Clinical and Translational Science Institute - Appendix A & B

    Oklahoma City, Oklahoma

  • Oregon Health and Science University - Appendix A & B

    Portland, Oregon

  • Kent Hospital - Appendix A & B

    Pawtucket, Rhode Island

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • National Neuromuscular Research Institute - Appendix A & B

    Austin, Texas

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.